FY2024 EPS Estimates for Opus Genetics Cut by HC Wainwright

Opus Genetics, Inc. (NASDAQ:IRD) – Analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Opus Genetics in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings of ($1.22) per share for the year, down from their previous estimate of ($1.11). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.11) per share. HC Wainwright also issued estimates for Opus Genetics’ Q4 2024 earnings at ($0.34) EPS, FY2025 earnings at ($1.03) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.53) EPS and FY2028 earnings at ($0.23) EPS.

Opus Genetics (NASDAQ:IRD) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.01. The firm had revenue of $3.87 million during the quarter, compared to analysts’ expectations of $1.17 million. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%.

Opus Genetics Price Performance

IRD opened at $1.06 on Friday. Opus Genetics has a 12 month low of $0.97 and a 12 month high of $3.40. The firm has a market cap of $33.46 million, a P/E ratio of -0.97 and a beta of 0.22.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.